TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29983113

Group type: EXPERIMENTAL
Intervention: Community health worker home visiting during antenatal and postnatal periods
Number of subjects: 1320

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 1320
Study: 26574871

Group type: EXPERIMENTAL
Intervention: Isoflurane (ISO) anesthesia maintained with 2 MAC and nitrous oxide 50%
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Sevoflurane (SEVO) anesthesia maintained with 2 MAC and nitrous oxide 50%
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Sevoflurane (SEVO)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Isoflurane (ISO)
Number of subjects: 60
Study: 24311703

Group type: EXPERIMENTAL
Intervention: New TRO-CTA protocol (non-ECG-gated low kVp scan at 80 kVp)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional TRO-CTA protocol (retrospective ECG-gating at 120 kVp)
Number of subjects: 60
Study: 23795897

Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 8884

Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 8884

Group type: EXPERIMENTAL
Intervention: Baseline ST-segment depression (1.0 mm vs no/0.5 mm)
Number of subjects: 8884

Group type: EXPERIMENTAL
Intervention: Baseline ST-segment depression (>1.0 mm)
Number of subjects: 8884

Group type: EXPERIMENTAL
Intervention: Discharge ST-segment depression (1.0 mm)
Number of subjects: 8884

Group type: EXPERIMENTAL
Intervention: Discharge ST-segment depression (>1.0 mm)
Number of subjects: 8884
Study: 21092177

Group type: EXPERIMENTAL
Intervention: Kallikrein panel (total PSA, free PSA, intact PSA, hK2)
Number of subjects: 262

Group type: COMPARATOR
Intervention: Base model (PSA, age, DRE)
Number of subjects: 262
Study: 19034332

Group type: COMPARATOR
Intervention: Atorvastatin 20 mg/day (ATV)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg/day + Amlodipine 20 mg/day (ATV+AML)
Number of subjects: 26
Study: 16819567

Group type: EXPERIMENTAL
Intervention: Thermostable autohemoderivative
Number of subjects: 108

Group type: COMPARATOR
Intervention: Adequate measures to be comparable control
Number of subjects: 108
Study: 14600515

Group type: EXPERIMENTAL
Intervention: Cytomegalovirus-specific IFN-gamma production
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: HAART duration
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: HIV viral load
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (26 randomly selected individuals)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: CD4 cell counts, cytomegalovirus lymphocyte proliferation, IL-2, and IL-10
Number of subjects: 26
Study: 10898421

Group type: EXPERIMENTAL
Intervention: Unfractionated heparin
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: PEG-hirudin
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Dalteparin
Number of subjects: 154

Group type: COMPARATOR
Intervention: Composite end point (death, myocardial infarction, revascularization)
Number of subjects: 154

Group type: COMPARATOR
Intervention: One-month mortality
Number of subjects: 154
Study: 8882962

Group type: EXPERIMENTAL
Intervention: P-VEBEC regimen (epirubicin 50 mg/sqm, cyclophosphamide 300 mg/sqm, etoposide 100 mg/sqm on weeks 1, 3, 5, 7; vinblastine 5 mg/sqm and bleomycin 5 mg/sqm on weeks 2, 4, 6, 8; prednisone 50 mg/sqm/day for the first two weeks and then every other day) with rG-CSF 5 micrograms/Kg/day for 4 consecutive days starting on day 2 of every week.
Number of subjects: 100

Group type: COMPARATOR
Intervention: P-VEBEC regimen without rG-CSF (implied control group).
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: P-VEBEC regimen with rG-CSF.
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: P-VEBEC regimen in patients with diffuse large cell lymphomas (DLCL).
Number of subjects: 100
Study: 1563574

Group type: EXPERIMENTAL
Intervention: 1 mg promegestone
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: 0.5 mg promegestone
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: 10 mg lynestrenol
Number of subjects: 132
Study: 7472109

Group type: EXPERIMENTAL
Intervention: Ascorbic acid treatment
Number of subjects: 2

Group type: COMPARATOR
Intervention: Control (no ascorbic acid)
Number of subjects: 2
Study: 31959340

Group type: EXPERIMENTAL
Intervention: DCF (docetaxel, cisplatin, and fluorouracil)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: DCFRT (docetaxel, cisplatin, fluorouracil + 45 Gy radiotherapy)
Number of subjects: 124

Group type: COMPARATOR
Intervention: EMR (early metabolic response)
Number of subjects: 124
Study: 31117111

Group type: EXPERIMENTAL
Intervention: AI malignant probability using deep learning algorithms
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: AI malignant probability
Number of subjects: 0
Study: 28026777

Group type: EXPERIMENTAL
Intervention: Immersive P300-based BCI application with proprioceptive stimulation
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Proprioceptive feedback
Number of subjects: 2

Group type: COMPARATOR
Intervention: Control group of healthy subjects
Number of subjects: 2
Study: 26104068

Group type: EXPERIMENTAL
Intervention: ECHO intervention
Number of subjects: 57

Group type: COMPARATOR
Intervention: Standard home visitation program
Number of subjects: 57
Study: 23882708

Group type: EXPERIMENTAL
Intervention: Skin intrinsic fluorescence (SIF) measurement
Number of subjects: 1185

Group type: EXPERIMENTAL
Intervention: Multivariate analysis of clinical and technical factors
Number of subjects: 1185
Study: 21853612

Group type: EXPERIMENTAL
Intervention: Infusion solution 'potassium and magnesium asparginate' at a rate of 1.5-2 ml/kg/h (n = 44)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Magnesium free crystalloid solutions (n = 33)
Number of subjects: 77
Study: 19320673

Group type: EXPERIMENTAL
Intervention: Web-based assessment and feedback (THRIVE)
Number of subjects: 7237

Group type: COMPARATOR
Intervention: Screening alone (Control)
Number of subjects: 7237
Study: 18174969

Group type: EXPERIMENTAL
Intervention: Grazax (Timothy-grass pollen extract) administered sublingually
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 16948861

Group type: EXPERIMENTAL
Intervention: Cissus quadrangularis formulation (two daily doses)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Cissus quadrangularis formulation with diet (2100‐2200 calories/day)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Cissus quadrangularis formulation without diet
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Cissus quadrangularis formulation (no diet)
Number of subjects: 123
Study: 12901993

Group type: EXPERIMENTAL
Intervention: Resin-modified glass ionomer cement (Fuji Plus)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Resin composite (Panavia 21)
Number of subjects: 29
Study: 10583024

Group type: COMPARATOR
Intervention: Risedronate administered 2 h after dinner
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Risedronate administered 1 h before a meal
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Risedronate administered 0.5 h before a meal
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Risedronate administered 4 h before a meal
Number of subjects: 127
Study: 9139271

Group type: EXPERIMENTAL
Intervention: Heart infarction with Q wave (group I)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Heart infarction without Q wave (group II)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 80
Study: 1819621

Group type: EXPERIMENTAL
Intervention: Aztreonam (1 g intravenously or intramuscularly, twice daily)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Ceftazidime (1 g intravenously or intramuscularly, twice daily)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Amikacin (500 mg intravenously or intramuscularly, twice daily)
Number of subjects: 76
Study: 6291832

Group type: EXPERIMENTAL
Intervention: MK 421 (10 mg p.o.)
Number of subjects: 12
Study: 29626552

Group type: EXPERIMENTAL
Intervention: Call it Quits intervention (five-session program delivered by case-workers)
Number of subjects: 431

Group type: COMPARATOR
Intervention: Usual care control group
Number of subjects: 431
Study: 28581397

Group type: EXPERIMENTAL
Intervention: Induction chemotherapy followed by concurrent chemo-IMRT
Number of subjects: 102

Group type: COMPARATOR
Intervention: Concurrent chemo-IMRT alone
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: V40 > 85%
Number of subjects: 102

Group type: COMPARATOR
Intervention: V40 ≤ 85%
Number of subjects: 102
Study: 24028173

Group type: EXPERIMENTAL
Intervention: TPB-based intervention in 18 intervention schools
Number of subjects: 2021

Group type: COMPARATOR
Intervention: Control group in 26 control schools
Number of subjects: 2021
Study: 23254543

Group type: EXPERIMENTAL
Intervention: SBST (static stretching before each strength training session)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: SDST (static stretching before each training set)
Number of subjects: 30

Group type: COMPARATOR
Intervention: OST (no stretching exercise)
Number of subjects: 30
Study: 21925996

Group type: EXPERIMENTAL
Intervention: Aliskiren/amlodipine 300/10 mg
Number of subjects: 489

Group type: COMPARATOR
Intervention: Amlodipine 10 mg
Number of subjects: 489
Study: 18179455

Group type: EXPERIMENTAL
Intervention: Bremelanotide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 15867121

Group type: EXPERIMENTAL
Intervention: Participation in a learning collaborative project based on the Breakthrough Series methodology of continuous quality improvement
Number of subjects: 13878

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 13878
Study: 14559422

Group type: EXPERIMENTAL
Intervention: Release from lower height (one‐knee height)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Release from higher height (three‐quarters of knee to shoulder distance)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Increasing release load (20, 40, 60, 80 N) at lower height
Number of subjects: 10

Group type: COMPARATOR
Intervention: Increasing release load (20, 40, 60, 80 N) at higher height
Number of subjects: 10
Study: 9892313

Group type: EXPERIMENTAL
Intervention: Intramuscular flunitrazepam (1 mg i.m.)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Intramuscular haloperidol (5 mg i.m.)
Number of subjects: 28
Study: 8694035

Group type: EXPERIMENTAL
Intervention: Estrogen replacement therapy (micronized estradiol, 2 mg/day)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 1911460

Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 32

Group type: COMPARATOR
Intervention: Dexamethasone
Number of subjects: 32
Study: 7112304

Group type: EXPERIMENTAL
Intervention: Disposable skin stapler (Proximate; Ethicon)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nylon sutures
Number of subjects: 0
Study: 31448928

Group type: EXPERIMENTAL
Intervention: Mindfulness training
Number of subjects: 40

Group type: COMPARATOR
Intervention: Coding training (active control)
Number of subjects: 40
Study: 27553981

Group type: EXPERIMENTAL
Intervention: Diaphragmatic breathing relaxation (DBR) training program
Number of subjects: 0
Study: 26504795

Group type: EXPERIMENTAL
Intervention: HCARE (high-concentration ashwagandha root extract) 300mg twice daily for 8 weeks
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo (starch) 300mg twice daily for 8 weeks
Number of subjects: 50
Study: 23829946

Group type: EXPERIMENTAL
Intervention: Healthy Eating (HE)
Number of subjects: 880

Group type: EXPERIMENTAL
Intervention: Physical Activity (PA)
Number of subjects: 880

Group type: EXPERIMENTAL
Intervention: HE + PA
Number of subjects: 880

Group type: EXPERIMENTAL
Intervention: HE + PA + Vitamin D
Number of subjects: 880

Group type: EXPERIMENTAL
Intervention: HE + PA + Placebo
Number of subjects: 880

Group type: EXPERIMENTAL
Intervention: Vitamin D alone (1600 IU)
Number of subjects: 880

Group type: EXPERIMENTAL
Intervention: Placebo alone
Number of subjects: 880

Group type: COMPARATOR
Intervention: Control
Number of subjects: 880
Study: 22768174

Group type: EXPERIMENTAL
Intervention: Valsartan (VAL, 320 mg/d)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo (PLB)
Number of subjects: 38
Study: 19180484

Group type: EXPERIMENTAL
Intervention: Chondroitins 4 and 6 sulfate (CS) 800 mg once daily for 2 years
Number of subjects: 622

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 622

Group type: EXPERIMENTAL
Intervention: Chondroitins 4 and 6 sulfate (CS)
Number of subjects: 622
Study: 17410467

Group type: EXPERIMENTAL
Intervention: Rebamipide (100 mg t.i.d.) with ibuprofen (1800 mg/day)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo with ibuprofen (1800 mg/day)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 20
Study: 15179130

Group type: EXPERIMENTAL
Intervention: Hydrocortisone therapy
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard care (reference group)
Number of subjects: 40
Study: 11490212

Group type: EXPERIMENTAL
Intervention: Intraurethral PGE2 gel (1 mg)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Intracavernous papaverine (60 mg)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 22
Study: 8991296

Group type: EXPERIMENTAL
Intervention: Hypnosis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no hypnosis, context reinstatement, or motivational instructions)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anxiety levels
Number of subjects: 0
Study: 11767426

Group type: EXPERIMENTAL
Intervention: Hydroxyzine 100 mg
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Hydroxyzine 100 mg and cimetidine 400 mg
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Hydroxyzine 100 mg and effervescent cimetidine (cimetidine 200 mg + sodium citrate 1.8 g)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Effervescent cimetidine orally in 30 ml of water 5 min before anaesthetic induction
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (Hydroxyzine 100 mg)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (Hydroxyzine 100 mg and cimetidine 400 mg)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (Hydroxyzine 100 mg and effervescent cimetidine)
Number of subjects: 80
Study: 3440226

Group type: EXPERIMENTAL
Intervention: Prochlorperazine 10 mg
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Prochlorperazine 20 mg
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Prochlorperazine 30 mg
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Prochlorperazine 40 mg
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Prochlorperazine (30 mg or 40 mg)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Prochlorperazine (all doses)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Prochlorperazine (higher-than-conventional doses)
Number of subjects: 71
Study: 29501358

Group type: EXPERIMENTAL
Intervention: Nurse gender
Number of subjects: 400

Group type: COMPARATOR
Intervention: Nurse race
Number of subjects: 400

Group type: COMPARATOR
Intervention: Patient gender
Number of subjects: 400

Group type: COMPARATOR
Intervention: Patient race
Number of subjects: 400
Study: 27537084

Group type: EXPERIMENTAL
Intervention: Donepezil
Number of subjects: 235

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 235
Study: 23604252

Group type: EXPERIMENTAL
Intervention: Goldmann applanation tonometry (GAT) without fluorescein
Number of subjects: 200

Group type: COMPARATOR
Intervention: Goldmann applanation tonometry (GAT) with fluorescein
Number of subjects: 200
Study: 22518026

Group type: EXPERIMENTAL
Intervention: Vasopressin
Number of subjects: 779

Group type: COMPARATOR
Intervention: Norepinephrine
Number of subjects: 779
Study: 20072816

Group type: EXPERIMENTAL
Intervention: 90-min IOOV
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: 30-min IOOV
Number of subjects: 200

Group type: COMPARATOR
Intervention: 30-min education
Number of subjects: 200
Study: 18728643

Group type: EXPERIMENTAL
Intervention: Docetaxel-cisplatin (D 60 mg m(‐2) and P 80 mg m(‐2) on day 1, every 3-4 weeks)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Docetaxel monotherapy (D 70 mg m(‐2), every 3 weeks)
Number of subjects: 80
Study: 16760295

Group type: COMPARATOR
Intervention: FOLFIRI regimen (arm A)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: FOLFIRI plus celecoxib 400 mg twice daily for 14 days (arm B)
Number of subjects: 81
Study: 12648175

Group type: EXPERIMENTAL
Intervention: Single dose of 50 micro g of intravaginal misoprostol
Number of subjects: 104

Group type: COMPARATOR
Intervention: Two consecutive doses of intravaginal 50 micro g misoprostol 6 h apart
Number of subjects: 104
Study: 11526759

Group type: EXPERIMENTAL
Intervention: Triptorelin (group B)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Thermocoagulation (group A)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Monitored methods of treatment (group C)
Number of subjects: 69
Study: 9187067

Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor (G-CSF)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 138
Study: 8243430

Group type: COMPARATOR
Intervention: Non-alcohol beer with 0% alcohol (A)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Non-alcohol beer with 2.7% alcohol (B)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Non-alcohol beer with 5.4% alcohol (C)
Number of subjects: 10
Study: 3798264

Group type: EXPERIMENTAL
Intervention: Midazolam (Dormicum; Roche) 0.1 mg/kg
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 31848786

Group type: EXPERIMENTAL
Intervention: Extra-trees model
Number of subjects: 155

Group type: COMPARATOR
Intervention: Random forest model
Number of subjects: 155

Group type: COMPARATOR
Intervention: Clinical measurements (average macular ganglion cell-inner plexiform layer thickness)
Number of subjects: 155

Group type: COMPARATOR
Intervention: Clinical measurements (average circumpapillary retinal nerve fiber layer thickness)
Number of subjects: 155
Study: 31050955

Group type: EXPERIMENTAL
Intervention: Laser-activated irrigation using PIPS with 17% EDTA and 5.25% NaOCl
Number of subjects: 56

Group type: COMPARATOR
Intervention: Conventional irrigation with 5.25% sodium hypochlorite (NaOCl)
Number of subjects: 56
Study: 28768327

Group type: EXPERIMENTAL
Intervention: Unified Protocol (UP)
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: Single-Disorder Protocols (SDPs)
Number of subjects: 223

Group type: COMPARATOR
Intervention: Waitlist Control
Number of subjects: 223
Study: 26184061

Group type: EXPERIMENTAL
Intervention: Knowledge of Performance (KP) - auditory and kinaesthetic combined
Number of subjects: 36

Group type: COMPARATOR
Intervention: Knowledge of Results (KR)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Kinaesthetic KP
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Auditory KP
Number of subjects: 36
Study: 22795722

Group type: EXPERIMENTAL
Intervention: Incremental maximal cycle exercise
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation of the motor cortex
Number of subjects: 20
Study: 21944697

Group type: EXPERIMENTAL
Intervention: Lifestyle modification and stress reduction intervention (LG)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Written advice only (AG)
Number of subjects: 96
Study: 19583930

Group type: EXPERIMENTAL
Intervention: Western medicine combined with Songling Xuemaikang Capsule (SXC)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Western medicine
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Western medicine combined with SXC
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: SXC
Number of subjects: 70

Group type: COMPARATOR
Intervention: Routine group
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 70
Study: 17113893

Group type: EXPERIMENTAL
Intervention: Electric Stimulation (ES)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Oxybutynin (2.5 mg three times per day)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Oxybutynin
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study: 14969611

Group type: EXPERIMENTAL
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 988

Group type: COMPARATOR
Intervention: Stent-assisted percutaneous coronary intervention (PCI)
Number of subjects: 988
Study: 11482635

Group type: EXPERIMENTAL
Intervention: 8‐hr team-oriented training
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: 4‐hr informational training
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: Both training groups
Number of subjects: 260

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 260
Study: 9764338

Group type: EXPERIMENTAL
Intervention: Simultaneous treatment with DEC (6 mg/kg) and ivermectin (200 micrograms/kg)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Simultaneous treatment with DEC (6 mg/kg) and ivermectin (400 micrograms/kg)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Sequential treatment with ivermectin (200 micrograms/kg) followed by DEC (6 mg/kg) after 5 days
Number of subjects: 31
Study: 8311599

Group type: EXPERIMENTAL
Intervention: Laxative, nonpulsatile perfusion
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Laxative, pulsatile perfusion
Number of subjects: 60

Group type: COMPARATOR
Intervention: No laxative, nonpulsatile perfusion
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: No laxative, pulsatile perfusion
Number of subjects: 60
Study: 3414920

Group type: EXPERIMENTAL
Intervention: Soluble aspirin 600 mg orally one hour before surgery
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Tubocurarine 0.05 mg/kg before induction of anaesthesia
Number of subjects: 84

Group type: COMPARATOR
Intervention: No pretreatment
Number of subjects: 84
Study: 1500629

Group type: EXPERIMENTAL
Intervention: Nasal beclomethasone dipropionate (Bdp) 336 micrograms/day
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 999409

Group type: EXPERIMENTAL
Intervention: Chlorpromazine (12.5 mg/70 kg, i.m.)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chlorpromazine (25 mg/70 kg, i.m.)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chlordiazepoxide (25 mg/70 kg, i.m.)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chlordiazepoxide (50 mg/70 kg, i.m.)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Morphine (15 mg/70 kg, i.m.)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Morphine (30 mg/70 kg, i.m.)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0